Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Total Debt (2021 - 2025)

Indivior Pharmaceuticals (INDV) has 5 years of Total Debt data on record, last reported at $319.0 million in Q4 2025.

  • For Q4 2025, Total Debt fell 4.2% year-over-year to $319.0 million; the TTM value through Dec 2025 reached $319.0 million, down 4.2%, while the annual FY2025 figure was $319.0 million, 4.2% down from the prior year.
  • Total Debt reached $319.0 million in Q4 2025 per INDV's latest filing, down from $322.0 million in the prior quarter.
  • Across five years, Total Debt topped out at $333.0 million in Q4 2024 and bottomed at $240.0 million in Q4 2022.
  • Average Total Debt over 5 years is $293.9 million, with a median of $320.5 million recorded in 2025.
  • Peak YoY movement for Total Debt: soared 38.75% in 2024, then decreased 4.2% in 2025.
  • A 5-year view of Total Debt shows it stood at $242.0 million in 2021, then dropped by 0.83% to $240.0 million in 2022, then changed by 0.0% to $240.0 million in 2023, then skyrocketed by 38.75% to $333.0 million in 2024, then decreased by 4.2% to $319.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Debt were $319.0 million in Q4 2025, $322.0 million in Q3 2025, and $326.0 million in Q2 2025.